Skandinaviska Enskilda Banken (SEB)
KYTX icon

Skandinaviska Enskilda Banken (SEB)’s Kyverna Therapeutics KYTX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-26,195
Closed -$128K – 868
2024
Q3 		$128K Hold
26,195
– – ﹤0.01% 750
2024
Q2 		$196K Buy
26,195
+9,385
+56% +$143K ﹤0.01% 713
2024
Q1 		$418K Buy
+16,810
New +$469K ﹤0.01% 712

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s KYTX Position: Q4 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 26,195 shares — an estimated $128K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in KYTX in Q1 2024 and held it in 3 quarters. The position peaked at $418K in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 26,195 Kyverna Therapeutics shares in Q4 2024, an estimated $128K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 3 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Kyverna Therapeutics position peaked at $418K in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2024, filed 10 Feb 2025.